Nuvalent Inc Class A NUVL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NUVL is a good fit for your portfolio.
News
-
Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024
-
Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024
-
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results
-
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520
-
Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors
Trading Information
- Previous Close Price
- $72.49
- Day Range
- $70.88–74.51
- 52-Week Range
- $36.00–89.37
- Bid/Ask
- $70.67 / $70.95
- Market Cap
- $4.57 Bil
- Volume/Avg
- 138,892 / 492,692
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company’s operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 92
- Website
- https://www.nuvalent.com
Comparables
Valuation
|
Metric
|
NUVL
|
CLDX
|
IGMS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 6.46 | 5.12 | 2.74 |
Price/Sales | — | 276.98 | 232.83 |
Price/Cash Flow | — | — | — |
Price/Earnings
NUVL
CLDX
IGMS
Financial Strength
|
Metric
|
NUVL
|
CLDX
|
IGMS
|
|---|---|---|---|
Quick Ratio | 22.62 | 13.69 | 7.95 |
Current Ratio | 22.83 | 13.87 | 8.18 |
Interest Coverage | — | — | — |
Quick Ratio
NUVL
CLDX
IGMS
Profitability
|
Metric
|
NUVL
|
CLDX
|
IGMS
|
|---|---|---|---|
Return on Assets (Normalized) | −19.79% | −30.49% | −44.52% |
Return on Equity (Normalized) | −20.76% | −33.19% | −84.37% |
Return on Invested Capital (Normalized) | −25.56% | −32.85% | −77.23% |
Return on Assets
NUVL
CLDX
IGMS
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bybrynkvv | Gjfv | $559.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Krgmffhz | Qvqsz | $103.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Sdsxyvb | Qxpxnv | $103.3 Bil | |
MRNA
| Moderna Inc | Tdlvlwgg | Htgx | $48.1 Bil | |
ARGX
| argenx SE ADR | Cddrbcmt | Znns | $23.1 Bil | |
BNTX
| BioNTech SE ADR | Gwxlmgt | Gbvy | $21.7 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vcrdqvlr | Hbbygt | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dsxgdgylj | Glmbc | $15.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Kvjdwqbnw | Zgpwszx | $12.7 Bil | |
INCY
| Incyte Corp | Hmfhqzmp | Wfglkkh | $11.9 Bil |